Stevanato Group S.p.A.: Stevanato Group Reports First Quarter 2023 Financial Results

- Reiterates Full Year 2023 Guidance - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology

Related Keywords

United States ,United Kingdom ,Indiana ,Italy ,Franco Stevanato ,Franco Moro ,Development Expenses ,Stevanato Group ,Exchange Commission ,Company Investor Relations ,Solutions Segment ,Full Year ,Chief Executive Officer ,Diagnostic Solutions Segment ,Order Intake ,Investor Relations ,States Toll Free ,Constant Currency Revenue ,Adjusted Operating Profit ,Adjusted Operating Profit Margin ,Adjusted Net Profit ,Adjusted Diluted ,Capital Employed ,Net Cash ,Free Cash Flow ,Marketing Expenses ,Administrative Expenses ,Constant Currency ,Operating Profit ,Income Taxes ,Operating Activities ,Net Debt ,Intangible Assets ,Net Profit ,Stevanato ,Group ,Reports ,First ,Quarter ,023 ,Financial ,Results ,